Roche receives Japanese approval for lung cancer therapy

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Roche’s alectinib for treatment of people living with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase fusion gene-positive (ALK+).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Reid E, Suneja G, Ambinder RF, Ard K, Baiocchi R, Barta SK, Carchman E, Cohen A, Gupta N, Johung KL, Klopp A, LaCasce AS, Lin C, Makarova-Rusher OV, Mehta A, Menon MP, Morgan D, Nathwani N, Noy A, Palella F, Ratner L, Rizza S, Rudek MA, Taylor J, Tomlinson B, Wang CJ, Dwyer MA, Freedman-Cass DA Abstract People living with HIV (PLWH) are diagnosed with cancer at an increased rate over the general population and generally have a higher mortality due to delayed diagnoses, advanced cancer stage, comorbidities, immunosuppression, and cancer treatment disparities. Lack of guidelines and provider education has le...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Work by theNanotechnology Characterization Laboratory (NCL), a joint initiative of NCI, NIST, and the FDA, has led to the discovery of a novel combination chemotherapy. This combination is shown to have synergistic effects on cytotoxicity to cancer cells in vitro, and to cause a substantial decrease in tumor growth in preclinical tumor models in vivo. Combination therapy using these agents may enhance the response rate of different cancers to these drugs and may significantly reduce side effects by permitting a lower therapeutic dose to be administered. SAIC Frederick'' s Nanotechnology Characterization   Laboratory&n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
SummaryThe recent approval of anaplastic lymphoma kinase (ALK) inhibitors for the treatment ofALK-rearranged non-small cell lung cancer (NSCLC) has dramatically transformed cancer therapy. However, leptomeningeal metastases (LM) are frequent and often devastating complications ofALK-rearranged NSCLC, and treatment against LM remains challenging. Herein we report a case of a 19-year-old male diagnosed withALK-rearranged NSCLC with LM. He experienced heavy treatment before introduction of alectinib therapy, which continued for approximately 5.5  years with marked efficacy. However, he experienced recurrence of a bulbar ...
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
This article is intended to provide readers with an overview of chemistry, pharmacokinetic, pharmacodynamic and safety profile of brigatinib, which addresses an unmet medical need.
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
Conclusion: Cycloartobiloxanthone has anticancer activity against human lung cancer cells by triggering mitochondrial apoptotic caspase-dependent mechanism. This compound might have promising effects for cancer therapy.
Source: In Vivo - Category: Research Authors: Tags: Experimental Studies Source Type: research
The already available expensive conventional therapies for cancer like chemotherapy and radiotherapy have a number of side effects such as myelosuppression and neurological, cardiac, pulmonary, and renal toxicity, which pose serious harm to the quality of life. Therefore, there is a need to develop treatment options that include more potent and less toxic anticancer drugs as compared to existing drugs. Studies have shown that regular consumption of fruits and vegetables because of phytochemical compounds extracted from them inhibiting the activity of antioxidant and free radicals which in turn showing anti-cancer activitie...
Source: International Journal of Phytomedicine - Category: Science Authors: Source Type: research
In recent years, there has been a deeper understanding of the mechanisms of immune evasion by cancer cells. This has led to the development of a number of immune checkpoint inhibitors for cancer therapy. The first inhibitor to be approved was ipilumumab, a monoclonal antibody that works to activate the immune system by targeting CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), a protein receptor that downregulates the immune system. Ipilimumab inhibits CTLA4, which is important for dampening T cell responses at the priming phase in lymph nodes, and is approved for ...
Source: Cancer Epidemiology Biomarkers and Prevention - Category: Cancer & Oncology Authors: Tags: Lung Cancer: Oral Presentations - Invited Abstracts Source Type: research
Authors: Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N, Wu J, Ren X, Zhang J Abstract During the past decade, more than 10 targetable oncogenic driver genes have been validated in non-small cell lung cancer (NSCLC). Anaplastic lymphoma kinase (ALK) and ROS1 kinase are two new driver genes implicated in ALK- and ROS1-rearranged NSCLC. Inhibition of ALK and ROS1 by crizotinib has been reported to be highly effective and well tolerated in these patients. However, resistance to crizotinib emerges years after treatment, and increasing efforts have been made to overcome this issue. Here, we review the biology of ALK and ...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Health | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Pharmaceuticals